Poseida, Takeda Aim to Develop Non-viral Gene Therapies for Hemophilia

Poseida, Takeda Aim to Develop Non-viral Gene Therapies for Hemophilia

309265

Poseida, Takeda Aim to Develop Non-viral Gene Therapies for Hemophilia

Poseida Therapeutics and Takeda are working together to develop non-viral gene therapies for hemophilia and other genetic diseases. “Together with Takeda, we look forward to developing potential cures for a number of genetic diseases with high unmet need,” Eric Ostertag, MD, PhD, Poseida’s CEO, said in a press release. Hemophilia is one of many diseases caused by genetic mutations — errors in the code that provides cells with instructions to perform their various functions. Gene therapies aim…

You must be logged in to read/download the full post.